Literature DB >> 20568673

Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function.

Taihei Ito1, Shin Itakura, Ivan Todorov, Jeffrey Rawson, Sadaki Asari, Jonathan Shintaku, Indu Nair, Kevin Ferreri, Fouad Kandeel, Yoko Mullen.   

Abstract

BACKGROUND: Bone marrow-derived mesenchymal stem cells (MSCs) are known to produce vascular endothelial growth factor. We hypothesize that co-transplantation of MSCs and islets promotes revascularization and improves islet graft function.
METHODS: Lewis rat islets were infused into the liver of streptozotocin-diabetic syngeneic recipients or transplanted under the renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MSCs isolated from Lewis bone marrow and expanded in culture.
RESULTS: Co-transplantation of 500 islets and 107 MSCs (islet-MSCs) reversed diabetes in all eight recipients, whereas islet-alone transplantation achieved euglycemia in 3 of 10 recipients. With 300 islets, five of nine islet-MSCs and 1 of 10 islets-alone recipients reversed diabetes. Results of intravenous glucose tolerance tests performed on day 56 were significantly better in islet-MSCs than islet-alone recipients. One week after transplantation, well-preserved islet structure and higher number of capillaries were found in the liver of islet-MSCs recipients, whereas islet-alone grafts were fragmented with very few capillaries. Islets showed a similar morphology when transplanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significantly higher capillary per [beta]-cell ratio than that in islet-alone grafts (0.135+/-0.046 vs. 0.052+/-0.028 capillary segments per [beta]-cell, P<0.01). One week after transplantation, islets were surrounded by MSCs labeled with carboxyfluorescein succinimidyl ester or Qdot nanocrystals, and some labeled MSCs positively stained for vascular endothelial growth factor or von Willebrand factor.
CONCLUSION: Our results demonstrate the improvement of islet graft morphology and function by co-transplantation with MSCs. This improvement is attributable, at least in part, to the promotion of graft revascularization mediated by MSCs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20568673     DOI: 10.1097/tp.0b013e3181db09c4

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  103 in total

Review 1.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 2.  The stem cell niche should be a key issue for cell therapy in regenerative medicine.

Authors:  José Becerra; Leonor Santos-Ruiz; José A Andrades; Manuel Marí-Beffa
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 3.  Mesenchymal stem cells as feeder cells for pancreatic islet transplants.

Authors:  Valeria Sordi; Lorenzo Piemonti
Journal:  Rev Diabet Stud       Date:  2010-08-10

Review 4.  In vivo imaging of embryonic stem cell therapy.

Authors:  Han Jiang; Zhen Cheng; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-24       Impact factor: 9.236

5.  MRI/SPECT/Fluorescent Tri-Modal Probe for Evaluating the Homing and Therapeutic Efficacy of Transplanted Mesenchymal Stem Cells in a Rat Ischemic Stroke Model.

Authors:  Yaohui Tang; Chunfu Zhang; Jixian Wang; Xiaojie Lin; Lu Zhang; Yi Yang; Yongting Wang; Zhijun Zhang; Jeff W M Bulte; Guo-Yuan Yang
Journal:  Adv Funct Mater       Date:  2015-02-18       Impact factor: 18.808

6.  Preculturing Islets With Adipose-Derived Mesenchymal Stromal Cells Is an Effective Strategy for Improving Transplantation Efficiency at the Clinically Preferred Intraportal Site.

Authors:  Chloe L Rackham; Paramjeet K Dhadda; Aurélie M Le Lay; Aileen J F King; Peter M Jones
Journal:  Cell Med       Date:  2014-03-24

7.  Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation.

Authors:  Hao Wu; Wenli Lu; Ram I Mahato
Journal:  Pharm Res       Date:  2011-04-16       Impact factor: 4.200

8.  An oxygen plasma treated poly(dimethylsiloxane) bioscaffold coated with polydopamine for stem cell therapy.

Authors:  Mehdi Razavi; Avnesh S Thakor
Journal:  J Mater Sci Mater Med       Date:  2018-05-03       Impact factor: 3.896

Review 9.  Mesenchymal stem cells in the treatment of type 1 diabetes mellitus.

Authors:  Jana Katuchova; Denisa Harvanova; Timea Spakova; Rastislav Kalanin; Daniel Farkas; Peter Durny; Jan Rosocha; Jozef Radonak; Daniel Petrovic; Dario Siniscalco; Meirigeng Qi; Miroslav Novak; Peter Kruzliak
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

Review 10.  The potential of cell-based therapy for diabetes and diabetes-related vascular complications.

Authors:  Aaron Liew; Timothy O'Brien
Journal:  Curr Diab Rep       Date:  2014-03       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.